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Although there are high survival rates for children with acute lymphoblastic leukaemia, their outcome is often 
counterbalanced by the burden of toxic eﬀ ects. This is because reported frequencies vary widely across studies, 
partly because of diverse deﬁ nitions of toxic eﬀ ects. Using the Delphi method, 15 international childhood acute 
lymphoblastic leukaemia study groups assessed acute lymphoblastic leukaemia protocols to address toxic eﬀ ects 
that were to be considered by the Ponte di Legno working group. 14 acute toxic eﬀ ects (hypersensitivity to 
asparaginase, hyperlipidaemia, osteonecrosis, asparaginase-associated pancreatitis, arterial hypertension, posterior 
reversible encephalopathy syndrome, seizures, depressed level of consciousness, methotrexate-related stroke-like 
syndrome, peripheral neuropathy, high-dose methotrexate-related nephrotoxicity, sinusoidal obstructive syndrome, 
thrombo embolism, and Pneumocystis jirovecii pneumonia) that are serious but too rare to be addressed 
comprehensively within any single group, or are deemed to need consensus deﬁ nitions for reliable incidence 
comparisons, were selected for assessment. Our results showed that none of the protocols addressed all 14 toxic 
eﬀ ects, that no two protocols shared identical deﬁ nitions of all toxic eﬀ ects, and that no toxic eﬀ ect deﬁ nition was 
shared by all protocols. Using the Delphi method over three face-to-face plenary meetings, consensus deﬁ nitions 
were obtained for all 14 toxic eﬀ ects. In the overall assessment of outcome of acute lymphoblastic leukaemia 
treatment, these expert opinion-based deﬁ nitions will allow reliable comparisons of frequencies and severities of 
acute toxic eﬀ ects across treatment protocols, and facilitate international research on cause, guidelines for treatment 
adaptation, preventive strategies, and development of consensus algorithms for reporting on acute lymphoblastic 
leukaemia treatment.
Introduction
Acute lymphoblastic leukaemia accounts for 25% of all 
childhood cancers and has leapt from being universally 
fatal two generations ago, to having 5-year overall survival 
rates of more than 90% with the best contemporary 
treatment.1 However, a substantial number of patients 
have severe, fatal, or lifelong toxic eﬀ ects.2 The frequency 
of these toxic eﬀ ects varies widely across study protocols 
(appendix), which reﬂ ects not only the diﬀ erence in 
treatment intensities, but also the diverse deﬁ nitions of 
toxic eﬀ ects and the strategies for their identiﬁ cation and 
reporting, making meaningful comparisons of the risks 
of toxic eﬀ ects impossible.
The progressive intensiﬁ cation of acute lymphoblastic 
leukaemia treatment in the past three decades means 
that the chance of treatment-related death can now be 
equal to the chance of leukaemic relapse in low-risk 
patients.3 Accordingly, trials no longer aim only to 
introduce more powerful antileukaemic drugs, but also 
focus on minimising toxic eﬀ ects. Evaluation of the 
success of this approach depends on robust measurement 
of the toxic eﬀ ect burden within diﬀ erent groups in a 
trial, between diﬀ erent trials internationally, and between 
patient subsets deﬁ ned by clinical features or germline 
DNA variants.4
Deﬁ nitions for most organ toxic eﬀ ects already exist, 
and the US National Cancer Institute Common 
Terminology Criteria for Adverse Events (CTCAE)5 is 
widely used. However, the CTCAE describes many toxic 
eﬀ ects in very general terms, and was not developed to 
meet the speciﬁ c needs associated with childhood acute 
lymphoblastic leukaemia treatment. Additionally, the 
grades of toxic eﬀ ects that are identiﬁ ed and reported 
vary across protocols. Finally, the scientiﬁ c community 
uses various deﬁ nitions for several toxic eﬀ ects 
(appendix p 24) and there is a need for consensus 
deﬁ nitions across paediatric acute lymphoblastic 
leukaemia protocols.
Recognising the need for international collaboration 
on this issue, the Ponte di Legno consortium (PdL) 
established a toxicity working group (PTWG) to address 
serious adverse events associated with childhood acute 
lymphoblastic leukaemia treatment (appendix), and thus 
improve the outcomes of children with the disease.1 As a 
ﬁ rst step, the PTWG aimed to obtain consensus 
deﬁ nitions of 14 prioritised acute toxic eﬀ ects. We report 
the process and the ﬁ nal deﬁ nitions that have been 
approved by the PdL acute lymphoblastic leukaemia 
groups. We hope these deﬁ nitions will be valuable for 
reliable comparisons of data on toxic eﬀ ects emerging 
from various treatments for acute lymphoblastic 
leukaemia, for collaborative research addressing risk 
factors including host genome variants, and for strategies 
for the prevention or treatment of toxic eﬀ ects.
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Methods
Toxic eﬀ ects considered by the PTWG
Representatives from 15 PdL groups listed all acute toxic 
eﬀ ects of childhood lymphoblastic leukaemia treatment 
that are serious but either too rare to be addressed 
comprehensively within any single acute lymphoblastic 
leukaemia group, or needed consensus deﬁ nitions 
for reliable comparison of incidences and outcome 
(appendix p 22). After initial discussions, those 
representatives decided that the toxic eﬀ ects that were 
almost universally reversible and suﬃ  ciently common to 
be investigated within a single acute lymphoblastic 
leukaemia group—such as mucositis, bone-marrow and 
immune suppression, febrile neutropenia, skin rashes, 
hyper glycaemia, and several transient organ failures—
should not be pursued by the PTWG. Among the 
remaining toxic eﬀ ects, treatment-related mortality and 
invasive fungal infections (apart from Pneumocystis jirovecii 
pneumonia) had been addressed,6 or are being addressed 
at present by other international working groups. 
Transferral to an intensive care unit was deemed to be 
too greatly aﬀ ected by local logistics and resources to be 
included for consideration. Furthermore, the PTWG did 
not regard toxic eﬀ ects that have multiple and complex 
causes (such as hepatic failure) as candidates for PTWG 
consensus deﬁ nitions, although they might be relevant 
for future prospective registration to quantify and qualify 
the burden of antileukaemic treatment. Finally, the 
PTWG did not address several toxic eﬀ ects that were 
serious but already deﬁ ned and graded by the CTCAE 
with deﬁ nitions suitable for children with acute 
lymphoblastic leukaemia.
Formation of consensus deﬁ nitions
Since the pathogeneses and natural histories for most of 
the remaining 14 prioritised toxic eﬀ ects are poorly 
understood from a biological point of view, the PTWG 
chose a Delphi process for obtaining expert opinion-
based consensus deﬁ nitions for these toxicities.7,8 
The PTWG established an ad-hoc working group for 
each of the 14 toxicities, including a chair for each 
group, with initial representation of experts from at 
least three of the 15 involved acute lymphoblastic 
leukaemia groups, which were subsequently expanded 
after each face-to-face plenary PTWG meeting 
(appendix p 22). Each ad-hoc working group reviewed 
the present scientiﬁ c literature on their toxic eﬀ ect with 
a special focus on acute lymphoblastic leukaemia cohort 
publications, and reviewed the toxic eﬀ ect sections of 
13 treatment protocols currently used by PdL groups. 
Additionally, one author (MK) added information on 
the Japanese acute lymphoblastic leukaemia protocols 
because they were not available in English. Each ad-hoc 
working group’s results and considerations were 
debated within their collaborative acute lymphoblastic 
leukaemia group and at three consecutive face-to-face 
plenary meetings (ﬁ gure). These face-to-face discussions 
were open to other individuals from the PdL, even if 
they were not directly involved in developing the ﬁ nal 
toxic eﬀ ect deﬁ nitions. On the basis of discussions 
at these meetings and comments from the involved 
PdL acute lymphoblastic leukaemia groups, all groups 
ﬁ nalised and approved the deﬁ nitions of these 
14 toxicities (panel).
Findings
Although the acute lymphoblastic leukaemia protocols 
all have sections on treatment-related toxic eﬀ ects, none 
of the protocols assessed address all of the 14 toxic eﬀ ects 
listed in this report. When addressed, however, they 
use various deﬁ nitions (appendix p 24). Furthermore, 
although a speciﬁ c toxic eﬀ ect might be highlighted and 
described in detail by one acute lymphoblastic leukaemia 
treatment protocol (eg, posterior reversible encephalo-
pathy syndrome), other protocols might not mention 
Figure: Delphi process to reach consensus deﬁ nitions for 14 toxic eﬀ ects
PTWG=Ponte di Legno toxicity working group. CTCAE=National Cancer Institute Common Terminology Criteria for 
Adverse Events. PdL=Ponte di Legno. BFM= Berlin-Frankfurt-Münster. *Versions of the detailed PTWG document 
were circulated to all PdL groups for comments during September, 2014, and March, 2015, and are now included 
as the appendix. 
14 toxic eﬀects selected. An ad-hoc working group was established for each toxicity
Each ad-hoc working group developed and reﬁned: 
 •  The deﬁnition for their toxic eﬀect
 •  A section on their toxic eﬀect for a detailed supportive PTWG document* 
First face-to-face plenary meeting, April 25, 2014, at the International BFM Annual 
Meeting, Prague, Czech Republic 
Ad-hoc working groups presented their ﬁndings in standardised presentations: 
 •  How each acute lymphoblastic leukaemia protocol deﬁned and captured toxic eﬀects
 •  Emphasis on protocol diversities
 •  Implications of a toxic eﬀect for subsequent acute lymphoblastic leukaemia treatment 
 •  Weaknesses and challenges associated with present deﬁnitions
 •  Proposal for PTWG consensus deﬁnition
Second face-to-face plenary meeting, Dec 5, 2014, at the American Society of 
Hematology Annual Meeting, San Francisco, CA, USA
Ad-hoc working groups presented their ﬁndings in standardised presentations: 
 •  Discussion of each toxic eﬀect deﬁnition. Focus on clarity and clinical applicability
 •  Discussion of ﬁrst detailed PTWG document draft and the comments received 
  from PdL acute lymphoblastic leukaemia groups 
 •  Strategies for treatment modiﬁcation, capture of toxic eﬀects, and registration were
 not discussed further because the primary aim was to obtain consensus deﬁnitions
Third face-to-face plenary meeting, May 8, 2015, the International BFM Annual 
Meeting, Budapest, Hungary
Ad-hoc working groups presented their ﬁndings in standardised presentations: 
 •  Each toxic eﬀect deﬁnition ﬁnalised
 •  Discussion and ﬁnalisation of second draft of detailed PTWG document
27 toxic eﬀects considered by PTWG
13 excluded
 2 already addressed by other groups
 1 too aﬀected by local logistics and resources 
 6 multiple and complex causes
 4 already well deﬁned and graded by the CTCAE with 
  deﬁnitions suitable for children with acute lymphoblastic 
  leukaemia
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See Online for appendix
Panel: Consensus deﬁ nitions and gradings of 14 acute toxic eﬀ ects associated with treatment of childhood acute 
lymphoblastic leukaemia
Hypersensitivity to asparaginase
An adverse local or general response from exposure to 
asparaginase characterised by ﬂ ushing, rash, urticaria, drug 
fever, dyspnoea, symptomatic bronchospasm, oedema or 
angio-oedema, hypotension, and/or anaphylaxis. Grading:
• Mild: transient ﬂ ushing or rash, drug-induced fever <38°C.
• Severe: drug fever ≥38°C; allergy-related oedema or 
angio-oedema; dyspnoea and/or symptomatic 
bronchospasm with or without urticaria; and/or hypotension 
and anaphylaxis with indication for asparaginase infusion 
interruption and parenteral medication (eg, antihistamines, 
glucocorticosteroids).
Hyperlipidaemia
Triglycerides/cholesterol blood concentrations greater than 
upper normal limit (UNL). Grading:
1 Mild: triglycerides/cholesterol <10 times UNL.
2 Moderate: triglycerides/cholesterol 10–20 times UNL.
3 Severe: triglycerides/cholesterol >20 times UNL.
Routine measurements should be done only as part of research 
protocols. Dose modiﬁ cation based only on laboratory ﬁ ndings 
is not recommended.
Osteonecrosis
Osteonecrosis results from the temporary or permanent loss of 
the blood supply to the bones, which can cause pain, limitation 
in activity of daily living, and potentially the collapse of an 
articulating surface with enhanced pain and development of 
arthritis. The disorder should be conﬁ rmed by MRI. Grading:
1 Asymptomatic with ﬁ ndings only by MRI.
2 Symptomatic, not limiting or only slightly limiting self-care 
activity of daily living. Lesions only outside joint lines in 
non-weight-bearing bones.
3 Symptomatic, not limiting or only slightly limiting self-care 
activity of daily living. Lesions in weight-bearing bones or 
aﬀ ecting joint lines in non-weight-bearing bones.
4 Symptomatic with deformation by imaging of one or more 
joints and/or substantially limiting self-care activity of 
daily living.
Asparaginase-associated pancreatitis
At least two of three features must be fulﬁ lled: abdominal pain 
strongly suggestive of pancreatitis; serum lipase or amylase 
three or more times UNL; and characteristic imaging ﬁ ndings of 
pancreatitis (ultrasound, CT, or MRI). Re-exposure should only 
be considered in mild cases. Grading:
1 Mild: symptoms and enzyme elevations more than 
three times UNL that last less than 72 h.
2 Severe: symptoms and/or enzyme elevations more than 
three times UNL that last more than 72 h, or haemorrhagic 
pancreatitis, pancreatic abscess, or cyst.
3 Death from pancreatitis.
Arterial hypertension
Systolic blood pressure and/or diastolic blood pressure at or 
greater than the 95th percentile for sex, age, and height on 
three or more occasions (three consecutive days, or separate 
clinic visits if outpatient). Grading:
1 Systolic blood pressure/diastolic blood pressure in the 
90th–95th percentile for age and/or blood pressure 
exceeding 120/80 mm Hg.
2 Recurrent or persistent systolic blood pressure/diastolic 
blood pressure greater than the 95th percentile for age at 
three separate measurements or lasting more than 72 h 
with monotherapy indicated.
3 Recurrent or persistent systolic blood pressure/diastolic 
blood pressure greater than 95th percentile for age at 
three separate measurements or lasting more than 72 h and 
needing more than one drug or additional intensive 
treatment than grade 2 for blood pressure control.
4 Life-threatening consequences (eg, hypertensive crisis with 
transient or permanent neurological deﬁ cit and urgent 
intervention needed).
5 Death from hypertension.
Posterior reversible encephalopathy syndrome
Posterior reversible encephalopathy syndrome is a clinical diagnosis 
based on any combination of transient headache, confusion, 
seizures, and visual disturbances in combination with characteristic, 
but transient, contrast-enhanced and diﬀ usion-weighted imaging 
MRI ﬁ ndings. Diagnosis can be supported by electroencephalogram 
ﬁ ndings, occurrence during early months of treatment, and 
presence of arterial hypertension. No grading.
Seizures
A disorder characterised by sudden, involuntary skeletal muscle 
contractions of cerebral or brainstem origin. Grading:
1 Brief partial seizure.
2 Brief generalised seizure.
3 Multiple seizures despite medical intervention.
4 Life-threatening, prolonged, or repetitive seizures.
5 Death from seizures.
Depressed level of consciousness
Abnormal changes in level of arousal or altered content of a 
patient’s thought processes.
Quantiﬁ ed by Glasgow Coma Scale or the patient being alert 
(appears wakeful and aware of self and environment), lethargic 
(mild reduction in alertness), obtunded (moderate reduction in 
alertness with increased response time to stimuli), stuporous 
(deep sleep; arousal only by vigorous or repetitive stimulation 
and return to deep sleep when discontinued), or comatose 
(unconscious, sleep-like appearance and behaviourally 
unresponsive to all external stimuli).
(Continued on next page)
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that toxic eﬀ ect. Many protocols agree on individual toxic 
eﬀ ect deﬁ nitions and grading, especially when the 
CTCAE is applied,5 but no two protocols share identical 
deﬁ nitions of all toxic eﬀ ects, and no toxic eﬀ ect 
deﬁ nition is shared by all protocols. Some protocols 
request data capture of any grade of a toxic eﬀ ect, 
whereas other protocols only address the most severe 
grades. Additionally, the consequence of a speciﬁ c toxic 
eﬀ ect occurring varies by protocol, from complete 
withdrawal of an antileukaemic drug (eg, asparaginase 
after pancreatitis) to no consequences, including the 
acceptance of re-exposure, although this is not always 
speciﬁ cally stated. All details of consensus toxicity 
deﬁ nitions, including background, guidelines, and 
considerations before toxicity deﬁ nition, can be found in 
the appendix.
(Panel continued from previous page)
Can involve simple capabilities (speech, calculations, or spelling) 
and more complex modalities (emotions, behaviour, or 
personality) with confusion, disorientation, hallucinations, 
poor comprehension, or verbal expressive diﬃ  culty.
Methotrexate-related stroke-like syndrome
Neurotoxicity occurring within 21 days of intravenous or 
intrathecal methotrexate with three characteristics that all need 
to be fulﬁ lled:
• New onset of one or more of paresis or paralysis; movement 
disorder or bilateral weakness; aphasia or dysarthria; altered 
mental status including consciousness (eg, somnolence, 
confusion, disorientation, and emotional lability); and/or 
seizures with at least one of the other symptoms.
• Either characteristic, but often transient, white matter 
changes indicating leukoencephalopathy on MRI or a 
characteristic clinical course with waxing and waning 
symptoms usually leading to complete (sometimes partial) 
resolution within a week.
• No other identiﬁ able cause.
Characteristic oval-shaped lesions of the subcortical white 
matter (mostly frontal or parietal) on MRI are best seen on 
diﬀ usion-weighted (hyperintense) or apparent diﬀ usion 
coeﬃ  cient (hypointense) images. Can be graded 1–5 according 
to CTCAEv4.03 for encephalopathy.
Peripheral neuropathy
Peripheral motor or sensory neuropathy, including pain and 
constipation, due to inﬂ ammation or degeneration of the 
peripheral motor or sensory nerves. Grading:
1 Loss of deep tendon reﬂ exes, slight paraesthesia, numbness, 
or pain that does not limit instrumental activity of daily 
living or require treatment.
2 Moderate symptoms that somewhat limit instrumental 
activity of daily living (eg, alters ﬁ ne motor skills such as 
buttoning a shirt) and/or paraesthesia, numbness, or pain 
that are controllable by non-narcotic medications.
3 Severe symptoms limiting self-care activity of daily living, 
including gait impairment, inability to perform ﬁ ne motor tasks; 
and/or paraesthesia, numbness, or pain that require narcotics.
4 Complete paralysis or life-threatening consequences 
(eg, vocal cord paralysis) with urgent need for intervention, 
or severe pain that is not controlled by narcotics.
5 Death from peripheral neuropathy (eg, vocal cord paralysis).
High-dose methotrexate-related severe nephrotoxicity
Increase in plasma creatinine of more than 0·3 mg/dL 
(26·5 μmol/L) and/or a relative increase of 1·5 times greater 
than a baseline value (measured within 4 days prior to 
hydration preceding high-dose methotrexate) together with 
plasma methotrexate concentrations at one or more 
timepoints after initiation of the methotrexate infusion: 36 h 
methotrexate more than 20 μmol/L, 42 h methotrexate more 
than 10 μmol/L, and/or 48 h methotrexate more than 
5 μmol/L. Renal toxic eﬀ ects can be graded according to 
CTCAEv4.03.
Sinusoidal obstruction syndrome
Fulﬁ lment of at least three of ﬁ ve, otherwise unexplained, 
criteria: hepatomegaly; hyperbilirubinaemia more than UNL; 
ascites; weight gain of at least 5%; and thrombocytopenia 
(transfusion-resistant and/or otherwise unexplained by 
treatment [eg, myelosuppression]). Doppler ultrasound could 
document changes in hepatic portal venous ﬂ ow and rule out 
alternative causes, but normal ﬁ ndings do not exclude 
sinusoidal obstruction syndrome. Grading:
1 Mild: bilirubin less than 103 μmol/L and weight gain less 
than 5%.
2 Moderate: bilirubin 103–342 μmol/L and/or weight gain 
more than 5% or ascites.
3 Severe: bilirubin more than 342 μmol/L and/or respiratory 
or renal failure or hepatic encephalopathy.
4 Death due to sinusoidal syndrome.
Thromboembolism
Venous and/or arterial thromboembolism. Conﬁ rmation by 
imaging (ultrasonography, computed tomography, magnetic 
resonance imaging) or by autopsy is required for grade 2 and 
higher. Grading:
1 Superﬁ cial thrombophlebitis or central venous line-associated 
deep venous thrombosis without symptoms (eg, pain or 
shortness of breath) or objective signs (eg, swelling, 
discolouration, or collaterals); or causing only central venous 
line dysfunction. Systemic anticoagulation not given.
2A Asymptomatic thromboembolism (including asymptomatic 
cerebral thrombosis). Systemic anticoagulation is usually 
given (not evidence-based).
2B Symptomatic deep vein thrombosis, systemic 
anticoagulation indicated.
(Continued on next page)
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Hypersensitivity to asparaginase
Allergic reactions to asparaginase are frequent.9,10 
All protocols address hypersensitivity, but only a few 
address silent inactivation (ie, neutralising antibodies 
with reduced enzymatic activity), and then with 
various deﬁ nitions of trough levels and timepoints for 
measurements, and none address allergic-like reactions 
(eg, vomiting, stomach ache, or rash) without in-
activation of asparaginase or indications for change in 
treatment (appendix p 2). The PTWG reached consensus 
that deﬁ nitions of hypersensitivity, silent inactivation, 
and allergy-like reactions were needed, although each 
could pose practical clinical challenges. All but one 
group use pegylated asparaginase as front-line treatment. 
Because pegylated asparaginase becomes inactivated in 
virtually all patients with an allergic reaction irrespective 
of its severity,9 any degree of hypersensitivity should 
logically lead to a change from Escherichia coli-derived 
pegylated asparaginase to Erwinia chrysanthemi-derived 
asparaginase.10 In addition to the deﬁ nition of 
asparaginase hypersensitivity, the PTWG deﬁ ned silent 
inactivation in patients without clinical allergy as 
trough asparaginase activity levels less than the lower 
level of quantiﬁ cation (LLQ; preferably measured in 
two independent samples)—ie, a day 7 asparaginase 
activity level of less than 100 international units per L or 
a day 14 level of less than LLQ in case of biweekly 
pegylated asparaginase, or both; and a 48 h post-dose 
level of less than LLQ in case of E chrysanthemi-derived 
asparaginase (given two to three times a week).
Hyperlipidaemia
Both asparaginase and glucocorticosteroids can cause 
transient and occasionally severe hypertriglyceridaemia. 
This disorder could lead to toxic complications 
(eg, thrombosis and cardiovascular late eﬀ ects) 
although these complications are so far poorly 
documented.11 However, only a few protocols address 
this toxic eﬀ ect, mostly without a clear deﬁ nition, and 
only one protocol recommends routine monitoring of 
serum triglycerides for selected patients. The PTWG 
reached consensus on deﬁ ning severity of hyper-
triglyceridaemia on the basis of levels, and also that 
routine monitoring should only take place as part of a 
research strategy.
Osteonecrosis
Osteonecrosis is a very common side-eﬀ ect of acute 
lymphoblastic leukaemia treatment that is addressed by 
all protocols, although each has diverse deﬁ nitions12 and 
diﬀ ering guidelines for further glucocortico steroid 
treatment.12 None of the protocols clarify the role, 
interpretation, or classiﬁ cation of imaging.13 All but one 
protocol used the CTCAE for clinical grading. The PTWG 
reached consensus that MRI should be applied for 
conﬁ rmation of clinically symptomatic disease rather 
than for screening patients, and that MRI should only be 
used for screening within a research project.
Asparaginase-associated pancreatitis
Asparaginase-associated pancreatitis has low direct 
mortality, but is one of the most frequent causes of 
discontinuation of asparaginase treatment, which could 
increase risk of relapse.14 All but one protocol provides a 
deﬁ nition of asparaginase-associated pancreatitis, with 
grading using either the CTCAE criteria or some 
modiﬁ cation of the Atlanta criteria15 (ie, abdominal pain 
suggestive of acute pancreatitis; serum amylase or 
serum lipase, or both, at or more than 2–3 times upper 
normal limit; and imaging ﬁ ndings characteristic of 
acute pancreatitis) although with variation as to whether 
two or three criteria should be fulﬁ lled. Some protocols 
recommended measure ments of both amylase and 
lipase because a lipase measurement is more speciﬁ c 
and sensitive than an amylase measurement. Protocols 
with extended use of asparaginase generally recommend 
truncation of asparaginase treatment only in cases of 
severe asparaginase-associated pancreatitis.
(Panel continued from previous page)
3 Symptomatic pulmonary embolism, cardiac mural thrombus 
without cardiovascular compromise, symptomatic cerebral 
sinovenous thrombosis, or arterial ischaemic stroke; 
all require systemic anticoagulation/antiaggregation.
4 Life-threatening thromboembolism, including arterial 
insuﬃ  ciency, haemodynamic or neurological instability. 
Urgent intervention needed.
5 Death due to thromboembolism.
Pneumocystis jirovecii pneumonia
• Conﬁ rmed P jirovecii pneumonia: presence of P jirovecii 
organisms from a patient with fever, abnormal chest 
radiograph compatible with P jirovecii infection, and/or 
hypoxaemia.
• Probable P jirovecii pneumonia: pneumonia of 
undetermined origin (fever, P jirovecii pneumonia 
compatible chest radiograph, and/or hypoxaemia) and 
responding to empirical treatment with co-trimoxazole.
Presence of P jirovecii organisms identiﬁ ed through cytological 
examination (Gomori-Grocott or Gram-Weigert staining), 
P jirovecii-speciﬁ c PCR, or P jirovecii immunoﬂ uorescence in a 
lung sample (bronchoalveolar lavage, bronchial aspiration, 
transbronchial biopsy, transthoracic needle aspiration, lung 
biopsy, or sputum).
CTCAEv4.03=National Cancer Institute Common Terminology Criteria for adverse events 
version 4.03. 
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Arterial hypertension
Arterial hypertension is common, especially during the 
ﬁ rst months of antileukaemic treatment.16 However, 
none of the protocols address arterial hypertension as an 
isolated toxic eﬀ ect, instead mentioning it only in 
association with posterior reversible encephalopathy 
syndrome. The PTWG reached consensus that the 
American Academy of Pediatrics17 and the CTCAE 
guidelines should provide classiﬁ cations of hypertension 
that are applicable to its transient occurrence during 
acute lymphoblastic leukaemia treatment.
Posterior reversible encephalopathy syndrome
Although posterior reversible encephalopathy syn-
drome is a clinicoradiological entity that is frequently 
reported during the ﬁ rst months of acute lymphoblastic 
leukaemia treatment, reﬂ ecting disturbances of 
cerebrovascular autoregulation, and is inconsistently 
characterised by headache, altered mental status, 
seizures, and visual disturbances,18 seven protocols 
do not address it at all, and only one addresses it 
in detail. When addressed, protocols apply the CTCAE 
grading used for any encephalopathy, despite its 
restricted usefulness for posterior reversible encephal-
opathy syndrome. Except for postponing intrathecal 
treatment until symptoms resolve, no anti leukaemic 
treatment modiﬁ cations are recommended in any of the 
protocols.
Seizures
Seizures occur in about 10% of children with acute 
lymphoblastic leukaemia.19 Most acute lymphoblastic 
leukaemia protocols grade seizures clinically according 
to CTCAE grading, which does not require electro-
encephalography and excludes absence seizures, 
which are rare in childhood acute lymphoblastic 
leukaemia. Seizures can occur both as an isolated 
symptom, together with various other toxic eﬀ ects of 
the CNS (eg, intracranial haemorrhage or thrombosis, 
posterior reversible encephalopathy syndrome, and 
methotrexate related stroke-like syndrome), and 
second to infections and electrolyte and metabolic 
disturbances. The PTWG decided not to include 
causation in the deﬁ nition, but will address this 
complexity in the registration of seizures as a toxicity 
in the future.
Depressed level of consciousness
The protocols provide grading for encephalopathy in 
general, but not speciﬁ cally in the context of decreased 
consciousness or even coma, potentially reﬂ ecting the 
complexity of both classiﬁ cation of the toxic eﬀ ect itself 
and its multiple causes such as infection, altered body 
temperature, electrolyte and metabolic disturbances, 
vascular or neurological complications, and direct 
toxic eﬀ ects of chemotherapy. The PTWG consensus 
deﬁ nition is based on clinical ﬁ ndings only.
Methotrexate-related stroke-like syndrome
Methotrexate-related stroke-like syndrome, which is 
characterised by focal neurological deﬁ cits or hemi-
paresis, and often accompanied by disturbances in 
speech, or all three, often develops within 2 to 3 weeks 
after methotrexate administration, and can last hours to 
days during which symptoms can wax and wane.20,21 
All but one protocol provided grading for encephalopathy, 
although not speciﬁ cally for methotrexate-related 
stroke-like syndrome, and used the CTCAE or the US 
Eastern Cooperative Oncology Group criteria. Only 
ﬁ ve protocols address this syndrome, of which only one 
describes the characteristic symptoms in detail, and only 
a few providing (various) guidelines for methotrexate 
re-exposure once the methotrexate-related neurotoxicity 
has resolved. Although MRI will not always be able to 
conﬁ rm methotrexate-related stroke-like syndrome, it is 
included in the consensus deﬁ nition because of the 
characteristic changes it often shows, and its ability to 
distinguish between methotrexate-related stroke-like 
syndrome and posterior reversible encephalo pathy 
syndrome.
Peripheral neuropathy
Peripheral motor or sensory neuropathy, or both, are 
common and are generally caused by vincristine (in which 
case they are nearly always reversible).22 No protocols 
recommend discontinuation of vincristine except in cases 
of paralysis (occasionally caused by Charcot-Marie-Tooth 
disease), but several protocols recommend dose reduction 
in CTCAE grade 3–4 cases of paraesthesia or motor 
paralysis. This toxic eﬀ ect is addressed by all treatment 
protocols with the CTCAE grading, except for one group 
applying the Balis scale.23 The PTWG agreed to use the 
CTCAE grading with minor modiﬁ cations.
High-dose methotrexate-related nephrotoxicity
All protocols that include administration of high-dose 
methotrexate (2·5–5·0 g/m²) have clear, although 
diverse, guidelines for hydration, alkalinisation, and 
folinic acid rescue. The protocols diﬀ er in their deﬁ nition 
of delayed methotrexate elimination both with respect to 
methotrexate concentrations and timepoints from 
initiation of the methotrexate infusion. In cases of 
severely delayed elimination of methotrexate, less than 
half of the protocols include guidelines for the use of 
carboxypeptidase that enzymatically breaks down 
methotrexate to non-toxic metabolites.24 Because of the 
very strong association between renal impairment and 
delayed methotrexate clearance, both parameters were 
included in the consensus deﬁ nition.
Sinusoidal obstructive syndrome
Sinusoidal obstructive syndrome or veno-occlusive 
disease is most commonly seen after haemopoietic 
stem cell transplantation and during 6-thioguanine 
containing maintenance treatment, but rarely with 
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6-mercaptopurine-based maintenance treatment.25 
Although the general risks of hyperbilirubinaemia and 
elevations of amino transferases during acute lympho-
blastic leukaemia treatment are mentioned in most of 
the protocols, sinusoidal obstructive syndrome is not 
included in the CTCAE, and only two of the protocols 
speciﬁ cally address the syndrome, with only one 
including a deﬁ nition. The PTWG consensus deﬁ nition 
is based on the combinations of at least three of 
ﬁ ve clinical ﬁ ndings and does not require imaging, 
although imaging might be of diagnostic beneﬁ t in 
selected cases.
Thromboembolism
Most of the protocols address thromboembolic events, 
with all protocols grading them according to the CTCAE, 
but varying with respect to which grades are to be 
reported as severe adverse events. In cases of 
thromboembolism during asparaginase treatment, all 
six protocols that address the issue recommend 
re-exposure with asparaginase once the patient’s clinical 
condition has stabilised and low molecular weight 
heparin has been instituted.26 The PTWG consensus 
deﬁ nition of thromboembolism incorporates both 
localisation and severity of symptoms.
P jirovecii pneumonia
The high risk of P jirovecii pneumonia when prophylaxis 
for the infection is not given during treatment of 
childhood acute lymphoblastic leukaemia is recognised 
in all protocols, but they diﬀ er in their prescribed dose of 
prophylactic co-trimoxazole and in the required diagnostic 
criteria.27 The PTWG consensus deﬁ nition distinguishes 
between conﬁ rmed and probable P jirovecii pneumonia.
Discussion
In childhood acute lymphoblastic leukaemia, the term 
event-free survival traditionally encompasses ﬁ ve clear-
cut events, namely: death during induction; resistance to 
ﬁ rst-line treatment; relapse of acute lymphoblastic 
leukaemia; non-leukaemic death during clinical 
remission; and development of a second cancer.1 
Although this composite measure of treatment outcome 
seemed suﬃ  cient when life expectancy for children with 
acute lymphoblastic leukaemia was poor, it falls short of 
present needs. Although many patients with a late 
relapse or a second cancer have a fair chance of being 
cured by second-line treatment, we cannot currently 
reverse their chronic toxic eﬀ ects. Each year, thousands 
of children around the world are cured after treatment 
for acute lymphoblastic leukaemia. However, many of 
them will have been burdened by severe acute toxic 
eﬀ ects that can cause permanent organ damage, such as 
osteonecrosis, chronic pancreatitis, thrombosis, and 
neurotoxicity, and even more patients will develop 
additional severe late eﬀ ects that challenge their ability to 
establish and live a normal adult life.28,29
Although the cumulative risk of each of the 14 acute 
toxic eﬀ ects addressed in this report is about 5–10% or 
less, about half of all patients will be aﬀ ected by at least 
one of the 14 eﬀ ects.30 As such, in the overall evaluation 
of acute lymphoblastic leukaemia treatment protocols, 
there is a need for the development of strategies to 
quantify the overall acute and long-term burden of 
treatment and balance it against event-free survival. 
These strategies will require uniform reporting in trials 
of acute lymphoblastic leukaemia of both life-threatening 
and fatal toxic eﬀ ects and of toxic eﬀ ects that are 
associated with substantial late eﬀ ects.
The development of evidence-based preventive 
interventions for the toxic eﬀ ects of acute lymphoblastic 
leukaemia treatment require consensus deﬁ nitions of 
toxic eﬀ ects to compare outcome across protocols; 
common strategies for capture and registration of toxic 
eﬀ ects; and international collaboration to identify host 
genome variants and exposures (eg, antileukaemic 
treatment, co-medication, and food–drug interaction) 
associated with the risk of speciﬁ c toxic eﬀ ects. Not all 
toxic eﬀ ect deﬁ nitions presented in this Review are 
clear-cut, which mainly reﬂ ects their uncertain 
pathophysiology. Furthermore, several toxic eﬀ ects can 
have overlapping symptoms (such as from the CNS), 
making precise classiﬁ cation challenging. Additionally, 
guidelines for interventions can be directed towards the 
symptom (eg, seizures or hypertension due to posterior 
reversible encephalopathy syndrome) or the underlying 
pathology (eg, methotrexate-related stroke-like syndrome). 
Accordingly, future registrations of some organ toxic 
eﬀ ects should allow entry of both separate symptoms 
(eg, seizures) and a putative syndrome (eg, posterior 
reversible encephalopathy syndrome).
We developed the toxic eﬀ ect deﬁ nitions listed in this 
report after reviewing the existing scientiﬁ c literature and 
current acute lymphoblastic leukaemia protocols, and 
using the Delphi method to develop expert consensus 
deﬁ nitions.7,8 These deﬁ nitions are a starting point for 
developing evidence-based guidelines regarding optimum 
management and prevention strategies. Although the 
deﬁ nitions are supported by the PdL acute lymphoblastic 
leukaemia groups and should be widely applicable, their 
clinical and biological validity will emerge in parallel with 
their implementation, and a deeper understanding of 
the pathogenesis of the toxic eﬀ ects gained by relevant 
in-vitro and animal models and international research 
collaboration.
The present CTCAE criteria for toxic eﬀ ects are mostly 
clinical and their grading is generally based on a ﬁ ve 
grade scale. The CTCAE criteria beneﬁ t from their long 
history of use, and from the standardisation of number of 
grades and uniformity of deﬁ nitions. However, they are 
not speciﬁ cally adapted to the administered anticancer 
treatment and some toxic eﬀ ects (eg, osteonecrosis and 
infertility) are never life-threatening or fatal, thus 
reducing the number of grades. Furthermore, the 
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inclusion of medical intervention in several classiﬁ cations 
is controversial because it suggests that intervention is 
needed for a speciﬁ c grade of toxic eﬀ ect. Additionally, the 
deﬁ nition might also reclassify a patient if a decision is 
made to refrain from an intervention because of local 
practice or patient preference rather than just the severity 
of the toxic eﬀ ect. Finally, the deﬁ nition of toxic eﬀ ect 
grades should also be coherent with re-exposure 
guidelines for acute lymphoblastic leukaemia treatment 
(eg, asparaginase in cases of mild asparaginase-associated 
pancreatitis).
Because of national regulations, some trial groups will 
be mandated to continue to register toxic eﬀ ects 
according to speciﬁ c guidelines, such as the CTCAE 
(currently under revision)5 in the USA. These acute 
lymphoblastic leukaemia groups will need to consider 
toxic eﬀ ect capture and registration strategies that cover 
both systems to allow future reporting of their data in a 
format that allows reliable comparison of the toxic eﬀ ect 
proﬁ le with acute lymphoblastic leukaemia groups that 
use the PdL toxic eﬀ ect deﬁ nitions.
The subsequent, but equally challenging, goal for the 
PTWG is now to develop common strategies for toxic 
eﬀ ect capture and registration because targeting selected 
toxic eﬀ ects could favour their capture at the expense of 
non-targeted, but routinely registered, CTCAE-graded 
toxic eﬀ ects, even though the non-targeted toxic eﬀ ects 
might be equally important clinically.31 Additionally, the 
PTWG will address guidelines for drug re-exposures, 
explore the eﬀ ect of host genome variants on toxic eﬀ ect 
risks, and develop consensus algorithms that balance 
toxicity and eﬃ  cacy in composite assessments of the 
outcome of acute lymphoblastic leukaemia treatment. 
As such, although many toxic eﬀ ects that emerge when 
treating acute lymphoblastic leukaemia during 
childhood can be far more diﬃ  cult to capture than the 
classic ﬁ ve treatment failures, they are just as crucial to 
include in future intervention trials to improve the 
outcome of children with acute lymphoblastic leukaemia.
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